Proteome Sciences Reports Widened 2024 Loss Amid Strategic Expansion and Leadership Changes

Proteome Sciences’ 2024 Results: A Tale of Two Halves

When a biotech firm reports both an 18% surge in flagship product sales and a 40% wider annual loss, you know there’s a story brewing. Proteome Sciences’ 2024 results read like a financial thriller – complete with plot twists, strategic gambits, and a cliffhanger ending pointing to 2026.

The Numbers That Matter

• 📉 £3.41m net loss (2023: £2.44m loss)
• 🔄 Revenue dipped 3% to £4.89m, but TMT® sales jumped 18%
• 💷 Cash reserves halved to £1.13m (2023: £2.03m)
• 🌎 US orders tripled year-on-year to over £2m

“We’ve passed a significant inflection point – the pipeline now extends well into 2026.”
– Christopher Pearce, Executive Chairman

Behind the Headline Loss

While the red ink might alarm casual observers, the devil’s in the detail:

Strategic Investments Bite

The £899k cash burn funded critical expansions:

• 🔬 Second mass spectrometer installation
• 🇺🇸 San Diego lab establishment
• 🧪 DIA multiplex tag R&D

Services Sector Squeeze

Proteomic services revenue collapsed 47% to £0.87m as biotech R&D budgets froze. Yet the order book tells a different story – carryover work ballooned 10x to £1.3m, suggesting deferred revenue rather than demand destruction.

The Growth Engines Revving Up

1. TMT®: The Cash Cow Moos Louder

The 35-plex TMTpro™ launch proved timely, driving:

• 📈 18% revenue growth to £4.01m
• 🔮 40% more proteins detected in serum studies
• 🔄 Successful pivot to single-cell proteomics

2. DIA Tags: The Future in 6-Colour?

Their new DIA multiplex tags (DXT) could disrupt the $1.7bn proteomics market:

• 📜 Patents filed for 6-plex system
• 🤝 Licensing deals targeted for 2025
• ⚖️ Potential counterweight to TMT® reliance

Leadership Shuffle: Out With the Old…

January’s management exodus saw both CEO and CFO depart. While concerning, the Chairman insists this clears the deck for “an appropriate successor” to lead the next growth phase. The duo leaves having delivered:

• 🇺🇸 US beachhead in San Diego
• 🧫 Single-cell proteomics capability
• 🔗 DIA tag development

Risks: The Elephant in the Lab

With net liabilities hitting £6.5m and loans repayable on demand, liquidity remains tight. The saving grace? Patient creditors – including Chairman Pearce – extending repayment deadlines to April 2026.

The 2025 Inflection Point

Three trends could make or break the thesis:

1. US Services Lift-Off: San Diego lab now operational with $2m+ pipeline
2. DIA Adoption: New workflows could capture share from ELISA/SomaLogic
3. Single-Cell Scaling: First commercial projects completed; 2,000-cell analyses becoming routine

As Pearce notes, “The benefits from additional capacity will be more fully reflected in 2025 and 2026 revenues.” Translation? Today’s losses fund tomorrow’s growth – if execution holds.

Bottom Line: High Risk, Higher Reward?

Proteome Sciences walks a tightrope between liquidity concerns and transformative potential. For risk-tolerant investors, the 2026 pipeline and TMT® momentum might justify the ride. For others? Watch the DIA licensing deals – they’ll signal whether this is truly becoming a multi-product company.

AGM alert: Mark your diaries for 16 May 2025 at Allenby Capital. Expect pointed questions about cash runway and management succession.